| Project/Area Number |
12670879
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | KYUSHU UNIVERSITY |
|---|
Principal Investigator |
KUWABARA Yasuio Faculty of medicine, KYUSHU UNIVERSITY, Ass. Prof., 医学部・附属病院, 助教授 (30150436)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HAYASHI Kazutaka Faculty of medicine, KYUSHU UNIVERSITY, Assistant, 医学部・附属病院, 助手 (00325458)
NAKAGAWA Makoto Faculty of medicine, KYUSHU UNIVERSITY, Medical staff, 医学部・附属病院, 医員
SASAKI Masayuki Faculty of medicine, KYUSHU UNIVERSITY, Lecturer, 医学部・附属病院, 講師 (40240907)
TANIWAKI Takayuki Faculty of medicine, KYUSHU UNIVERSITY, Lecturer, 大学院・医学研究院, 講師 (80284496)
|
|---|
| Project Period (FY) |
2000 – 2001
|
| Project Status |
Completed (Fiscal Year 2001)
|
| Budget Amount *help |
¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 2001: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2000: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Keywords | positron emission tomography / dopamine d2 receptor / Parkinson's disease / Inhibitor of Monoamine Oxidase Type B / C-11 raclopride |
|---|
| Research Abstract |
We have studied reproducibility of measurements of D2 dopamine receptor binding potential with C-11 raclopridepositron emission tomography (PET). PET studies were performed in three-dimensional mode using the ECAT EXACT HR^+ (Siemens Corp.) with a spatial resolution of 3.6mm on the plane and an axial resolution of 4.2mm. For assessment of D2 receptor binding, 20 sequential scans were obtained over 60 minutes, starting at the time of injection of 37-494MBq of C-11 raclopride (specific activity = 120-1200Ci/mmol). Specific tracer uptake in the target region was calculated for each subject by subtracting cerebellum regions of interest (ROI) activity from target region's ROI activity and dividing the difference by cerebellum activity. The occipital lobe was also used for a reference region. The index was calculated for the transient equilibrium method. Four healthy volunteer were scanned with an interval of 1 to 12 months. The measure of binding potential (BP) showed good stability. After 1 to 12 months, the variability in striatum BP was -3.7 to 4.6%. There are no differences between using cerebellum and occipital lobe as a reference region. The injection dose and specific-activity did not affect the results. And then, we have studied 4 parkinson's disease patients before and after 1 week selegiline, an inhibitor of monoamine oxidase type B, treatment using PET and C-11 raclopride to asses whether selegiline causes changes of striatal dopaminergic D2 receptors. Two patients with selegiline resistance had increased values in puatmen and caudate uptake, while remaining two patients with selegiline responsiveness showed a reduction raclopride uptake. Thus, we could evaluate the effect of MAO-B inhibitor on dopaminergic system.
|
